MEDDDICAL Launches Insurance Claims Data & RWD Advisory Services for Pharma

MEDDDICAL launches advisory service connecting pharmaceutical and medtech companies with insurance claims data partners to generate real-world evidence for clinical development, regulatory submissions, post-market surveillance, and market access strategies.

Sotogrande, Spain, May 19, 2026 -- As pharmaceutical companies face increasing pressure to demonstrate product value in real-world settings, MEDDDICAL has launched a new advisory service focused on helping pharmaceutical and MedTech companies use insurance claims data and real-world evidence more strategically across development, market access, and commercialization. The service is designed for organizations evaluating healthcare datasets, claims analytics, and patient-level real-world data to support decision-making throughout the product lifecycle.

More information is available at https://medddical.com

According to Deloitte, nearly 70% of pharmaceutical executives said improving access to external real-world data sources and analytics is now a high strategic priority for commercial and development planning. Insurance claims datasets and healthcare databases are increasingly being used to evaluate treatment pathways, patient outcomes, healthcare utilization, and reimbursement trends outside traditional clinical trial settings.

At the same time, many organizations struggle to navigate the growing number of healthcare database providers, analytics platforms, and overlapping data vendors entering the market. The new advisory service from MEDDDICAL focuses on helping clients define their requirements before committing to large-scale licensing agreements, analytics investments, or long-term vendor partnerships. That process may include evaluating all payer claims databases, DRG claims data, longitudinal patient datasets, and broader pharma real-world data ecosystems tied to commercial analytics and evidence generation.

In addition, the service supports pharmaceutical and medtech teams exploring synthetic patient cohorts, patient journey mapping, competitive intelligence initiatives, and AI-driven analytics connected to market access and commercialization planning. According to MEDDDICAL, many internal teams have strong expertise in either clinical development or data analysis, but not always both. The company says its role is to help bridge that gap by aligning scientific goals, operational priorities, and compliance considerations before major investments are made.

Real-world evidence and claims-based analytics continue playing a larger role in how pharmaceutical and medtech organizations evaluate treatment effectiveness, understand payer behavior, and identify unmet needs across patient populations. The company's advisory approach is intended to help clients move from fragmented data exploration toward clearer evidence strategies that support both development and commercial objectives.

About MEDDDICAL

MEDDDICAL is an independent advisory service focused on real-world evidence (RWE) strategy for life sciences organizations. The company supports pharmaceutical and MedTech teams in evaluating data requirements, study design considerations, and regulatory alignment needs across clinical development and market access programs.

For more information, visit https://medddical.com/services/

Contact Info:
Name: Rainer Muller
Email: Send Email
Organization: MEDDDICAL
Address: Aptos 221 Edificio D2C, Sotogrande, Cadiz 11310, Spain
Website: https://medddical.com

Source: NewsNetwork

Release ID: 89192413

If there are any problems, discrepancies, or queries related to the content presented in this press release, we kindly ask that you notify us immediately at error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team will be available round-the-clock to address your concerns within 8 hours and take necessary actions to rectify any identified issues or support you with press release takedowns. Ensuring accurate and trustworthy information is our unwavering commitment.